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Introduction: Pemetrexed is approved to treat non-small cell lung
cancer and has an overall favorable toxicity profile. A case of
pemetrexed-induced cutaneous adverse events (CAE), i.e., perior-
bital edema with conjunctivitis and edema of the limbs, leading to
severe fluid retention, was diagnosed in our unit. The aim of this
study was to evaluate the incidence and risk factors for CAEs.
Methods: Patients treated with pemetrexed were identified from a
prospective cohort. To detect pemetrexed-associated CAEs, ques-
tionnaires were answered by patients and the referring oncologist.
Results: Included were 107 patients treated with four cycles or more
of pemetrexed. Pemetrexed-induced CAEs were observed in 37 of
107 (35%) total patients (TPs) and 25 of 47 (53%) alive patients
(APs). Conjunctivitis was the most frequent CAE: 27 of 107 (25%) in
TPs and 21 of 47 (44%) in APs. Periorbital edema occurred in 16 of 107
(15%) TPs and 14 of 47 (30%) APs. Limb edema was present in 14 of
107 (13%) TPs and 12 of 47 (25%) APs. Only two cases of CAE
influenced pemetrexed treatment. No significant differences in age,
body surface area, smoking status, and performance status were de-
tected. Patients with CAE had more cycles of pemetrexed (7 versus 5.5;
p  0.028). In univariate and multivariate analyses, gender ratio was
statistically different (p  0.031): 48% (12/25) of women in the CAE
group versus only 18% (4/18) in the control group.
Conclusion: Pemetrexed induces frequent conjunctivitis, peripheral
edema, and edema of the limbs. Female gender seems to be an
independent risk for CAE. CAEs are frequently disabling and
symptomatic treatment should be proposed.
Key Words: Lung cancer, Pemetrexed, Cutaneous side effect,
Periorbital edema, Conjunctivitis, Edema of the limbs, Scleroderma.
(J Thorac Oncol. 2011;6: 2083–2089)
Pemetrexed is an antifolate approved for the treatment ofnon-small cell lung cancer (NSCLC) and malignant pleu-
ral mesothelioma (MPM). Antifolates, i.e., fluorouracil,
methotrexate, and pemetrexed, are antineoplastic agents that
have been widely used to treat hematologic malignancies and
solid tumors. Folic acid is essential for the synthesis of
thymidine nucleotide, which is incorporated into DNA. The
cytotoxic activity of antifolates is due to their ability to inhibit
several folate-dependant enzymes involved in DNA synthe-
sis. Pemetrexed inhibits three key enzymes involved in the
synthesis of nucleotides: thymidylate synthase, dihydrofolate
reductase, and glycinamide ribonuleotide formyltransferase.1
Food and Drug Administration and European Medicines
Agency approval for pemetrexed was obtained as the front-
line treatment with a platinum agent in MPM and in nons-
quamous cell carcinoma (non-SCC).2 Pemetrexed has also
demonstrated its efficacy as a second-line3 or maintenance
therapy in non-SCC.4
The main toxicities associated with pemetrexed are
asthenia, nausea, diarrhea, myelosuppression, and rash.2 Cu-
taneous toxicities are frequently reported: 14% for pem-
etrexed alone (0.4% of grade 3/4)5 to 22% when combined
with cisplatin (0.6% of grade 3/4).2 Vitamin supplementation
by folic acid and vitamin B12 decreases the incidence of
grade 3/4 myelosuppression, mucositis, diarrhea, and fatigue.6 It
also decreases drug-related deaths.7 Prophylactic treatment with
oral corticosteroids has demonstrated a decrease in severe cuta-
neous toxicities and is systematically administered (prednisolone
50 mg/d or dexamethasone 4 mg twice daily for 3 days begin-
ning the day before pemetrexed).8 Few cases of pemetrexed-
induced cutaneous adverse event (CAE) have been reported,
mainly periorbital-facial edema9–11 and edema of the limbs.11
Lyell syndrome,12,13 radiation recall dermatitis,14,15 and urti-
carial vasculitis16 are exceptional. In clinical trials on pem-
etrexed, the descriptions of CAE are of low quality. Accord-
ing to the National Cancer Institute Common Toxicity
Criteria (version 4.0), skin and subcutaneous tissue disorders
include 34 classifiers, among these, 23 are assessed as 3
grade toxicities and are, therefore, not well discussed in the
literature reviews of pemetrexed toxicities.
In October 2008, we observed a case of pemetrexed-
induced CAE (periorbital edema with conjunctivitis and
edema of the limbs), which lead to severe fluid retention with
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bilateral pleural and pericardial effusions. The aim of this
study was to describe the CAEs, then to evaluate, in a cohort,
the incidence and risk factors for pemetrexed-induced CAE.
PATIENTS AND METHODS
Patients
In October 2008, a case of severe CAE was diagnosed.
This adverse drug reaction was reported to the pharmacovigi-
lance department. All patients with histologically proven
NSCLC, MPM, or other solid tumors who had received at
least four courses of pemetrexed, between October 2008 and
October 2009, were identified from the prospective database
of the centralized chemotherapy preparation unit of the Hoˆpi-
tal Tenon (J.F.). For each patient, the following characteris-
tics were collected: age, gender, body surface area, smoking
status, performance status at diagnosis (World Health Orga-
nization), tumor histology according to the World Health
Organization guidelines, and clinical tumor, node, and me-
tastasis tumor stage as defined by the 7th tumor, node, and
metastasis classification.17,18 Prior chemotherapy regimens
and combined platinum treatments were also recorded. The
patients were monitored until March 2010.
Pemetrexed Treatment
Pemetrexed was administered according to European
Medicines Agency approval: 500 mg/m2/cycle every 21 days,
with vitamin supplementation by folic acid (0.4 mg/d) and
vitamin B12 supplementation (1000 g intramuscularly ev-
ery 9 weeks) and corticosteroids prophylaxis (prednisolone
50 mg orally twice/day administered the day before, the day
of, and the day after chemotherapy). For the pemetrexed
treatment, the number of cycles, the cumulated dose, the
cumulated dose per body surface area, and tumor response at
the first evaluation were noted. Data on estimated glomerular
filtration rate and weight were collected at diagnosis and at
before and at the end of the pemetrexed treatment. Cases of
grade 3/4 hematologic toxicities were registered.
Identification of Pemetrexed-Induced CAE
To detect pemetrexed-induced CAE, i.e., conjunctivitis,
periorbital edema, and edema of the limbs, two question-
naires (see, Annexes 1 and 2, online supplementary data,
http://links.lww.com/JTO/A140) were designed by expert
dermatologists (B.E. and C.F.): one was for the patient and
the other for the referring oncologist. The questionnaires
were designed to (1) identify the occurrence of CAE during
or after the period of pemetrexed treatment, (2) characterize
the type of CAE, i.e., conjunctivitis, peripheral edema,
and/or periorbital edema, and (3) grade (1–3) CAE accord-
ing to National Cancer Institute Common Toxicity Criteria
(version 4.0, see, Annex 3, online supplementary data).
The description of the three grades of each symptom was
adapted to nondermatologist physicians to provide a pre-
cise evaluation of the adverse events. Concerning the
patients’ questionnaire, different grades of adverse events
were described with examples of disability corresponding
to each grade (see, Annexes 1 and 2, online supplementary
data, http://links.lww.com/JTO/A140).
A CAE was considered when the patient declared a
grade 1 adverse event, even if it was not declared by the
oncologist. Reporting of symptoms by patients is known to be
more sensitive than reporting by physicians.19 In cases of a
2/3 grade CAE with differences in patient’s and oncologist’s
reporting, only the oncologist’s evaluation was considered.
Patients with a grade 2/3 CAE were explored by a dermatol-
ogist. In patients not returning their questionnaire, informa-
tion reported by the oncologist was exclusively considered.
Patients with a history of severe cardiac, hepatic, kidney, or
respiratory insufficiency, or high-dose corticosteroids, cal-
cium channel blockers, or other drug-induced swelling were
excluded.
Finally, two groups of patients were considered: cases
(patients with CAE) and controls (patients without CAE).
Patients with a grade 2/3 CAE were separately analyzed.
Statistical Analyses
The statistical analyses were performed with Xnum-
bers56. For univariate analysis, a 2 test or Fisher’s exact test
for categorical variables and Student’s test for continuous
variables were used. Multivariate logistic regression models
were constructed to identify independent risk factors associ-
ated with a pemetrexed-induced CAE.
RESULTS
Description of the Index Case
A 67-year-old male, former smoker, had a 2-year his-
tory of diabetes mellitus treated with metformin. In October
2007, an advanced bronchioalveolar carcinoma was diag-
nosed. The patient received erlotinib (150 mg/d) as part of a
prospective trial (IFCT-0504 trial, NCT 00384826). In Janu-
ary 2008, a second line of treatment with carboplatin (area
under the curve 6, day 1 and every 28 days) and paclitaxel (90
mg/m2 on days 1, 8, and 15) was started because of the
cancer’s progression. After six cycles, weekly paclitaxel was
maintained (IFCT-0504 trial) and administered until June
2008 but had to be discontinued because of a grade 3
neuropathy. No cutaneous symptom was noted.
In October 2008, pemetrexed was introduced as third-
line chemotherapy. On days 3 to 10 of each cycle, the patient
reported a low-grade fever (38°C), erythematous edema of
the feet and hands, and noninfectious pruritic conjunctivitis.
An edema of the eyelid progressively extended to the rest of
the face, as well as edema of the extremities to the lower and
upper limbs.
In August 2009, after the 15th cycle of pemetrexed,
weight gain was maximal (14 kg). A physical examination
showed conjunctivitis (grade 1), a periorbital edema (grade 2),
and inflammatory edema of the lower and upper limbs (grade
3) (Figures 2A–C). He also presented with a bilateral pleural
effusion with a moderate pericardial effusion. Pleural analy-
sis showed a transudate (protides 23 g/liter) and no malignant
cells. Hypoalbuminemia at 25 g/liter, as well as biological
inflammation with CRP at 95 mg/liter and ferritin at 1800
mg/liter, was noted. Routine biology revealed macrocytic
anemia (8 g/dl) with normal liver and kidney function. Bone
marrow aspiration was normal. Brain natriuretic peptide anal-
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ysis and left ventricular ejection fraction by echocardiogra-
phy were within normal ranges. At this point, diagnoses of
fluid retention by the heart and liver or kidney failure were
excluded. High-resolution ultrasonography and MRI of the
soft tissue showed moderate lymphoedema with myositis.
Autoantibodies associated with autoimmune-related diseases
were negative, and the cutaneous, as well as the muscular
biopsies, showed moderate nonspecific lymphocytic infiltra-
tion of the conjunctive tissue (P.M.). As symptoms started
after the beginning of pemetrexed therapy and worsened after
each cycle, the final diagnosis of pemetrexed-induced CAE,
complicated by severe fluid retention, was strongly suspected.
This adverse effect was not associated with a deficiency of
folic acid or vitamin B12, as vitamin supplementation was
correct and serum vitamin levels were within normal ranges.
Pemetrexed was stopped. He was treated by diuretics and
albumin perfusion. Cutaneous inflammation was treated with
oral corticosteroids (prednisone 0.5 mg/kg/d for 14 days).
This therapy dramatically improved fluid retention and cuta-
neous inflammatory symptoms (Figure 1). Nevertheless, the
skin on his legs appeared sclerous, which was partially
improved by compression stockings and lymphatic drainage.
Comparison of Patients with CAE and without
CAE
From October 2008 to October 2009, 109 patients were
treated with pemetrexed for NSCLC or MPM and were
included in the study cohort (Figure 1, Table 1). Sixty
patients deceased, and 49 were alive at the end point, March
1, 2010. Two patients were excluded because they had other
etiologies of peripheral edema (right heart failure and ima-
tinib treatment). Questionnaires were answered by all oncol-
ogists (49/49, 100%) and 36 patients (36/49, 76%).
Descriptions and Incidences of
Pemetrexed-Induced CAE
Data concerning the total patients (TP) and alive pa-
tients (AP) were analyzed separately to limit the bias of
analysis of deceased patients (Table 2). Pemetrexed-induced
CAEs were observed in 35% (37/107) of TPs and 53%
(25/47) of APs (Figure 2). Conjunctivitis was the most
frequent adverse event, affecting 25% (27/107) of TPs and
44% (21/47) of APs. It was usually the first occurrence of
inflammatory CAE and appeared after two to six cycles of
pemetrexed, despite corticosteroid premedication. In APs,
conjunctivitis was mainly mild (grade 1), but had, in a third
of cases (7/21), an impact on daily activities (grade 2).
Seventy-six percent (16/21) of patients presented with con-
junctivitis, which subsequently developed into inflammatory
edema of the eyelid. Periorbital edema (15%, 16/107 of TPs,
and 30%, 14/47 of APs) and edema of the limbs (13%, 14/107
of TPs and 25%, 12/47 of APs) were almost as frequent
(Figure 3). Grade 3 toxicity exclusively concerned the index
case. Only two cases of CAE affected the ongoing treatment
with pemetrexed and caused temporary discontinuation.
Among the 47 alive patients, 11 (24%) had one or more
grade 2/3 CAEs (Table 3). Ten patients had conjunctivitis,
mostly grade 2 (7/11). Eight patients presented with at least
two of the three studied CAEs. The mean time to onset of the
CAE was 3 months after the first course of pemetrexed.
FIGURE 1. Study flow chart.
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Risk Factors for CAE
Risk factors were only analyzed for the 47 alive pa-
tients, which included 25 cases and 22 controls. Cases and
controls did not differ in age, body surface area, smoking
status, or performance status (Table 1). Nevertheless, 12 of
25 cases were women, whereas only 4 of 22 were controls
(p  0.03). Locally advanced or metastatic NSCLC was the
main indication for pemetrexed in both groups. Pemetrexed
was administered as a first- or second-line treatment in both
groups, and no significant difference in the response rate,
according to RECIST criteria, was noted. Nevertheless, the
cases received significantly more cycles of pemetrexed than
the controls (7 versus 5.5; p  0.028). The glomerular
filtration rates and the median weight changes were similar in
both groups, with no significant change after pemetrexed
treatment. Hematologic side effects were similar in both
groups (grade 3/4 anemia occurred in two cases and in five
controls). From multivariate analysis, only gender ratio (p 
0.04) remained statistically different.
Concerning the 11 cases with grade 2/3 CAEs (23%,
11/47), there were no significant statistical differences com-
pared with cases presenting with a grade 1 CAE (77%, 36/47)
concerning their clinical characteristics (age, body surface
area, NSCLC type, and renal function) or their treatment
characteristics (number of cycles and cumulative doses of
pemetrexed). Only two patients received pemetrexed as a
first-line treatment, and 8 of 11 patients received more than
six cycles of pemetrexed. Regarding previous chemothera-
pies, six patients received gemcitabine and two paclitaxel.
Both patients and oncologists noted that pemetrexed-induced
TABLE 1. Baseline Characteristics of the Study Population
All
(n  47)
Cases
(n  25)
Controls
(n  22)
p
(UV/MV)
Age at diagnosis (yr, median, IQR) 60 (54–66) 60 (57–67) 59 (49–66) NS
Gender
Male, n (%) 31 (66) 13 (52) 18 (82) 0.031/0.04
Female, n (%) 16 (24) 12 (48) 4 (18)
Smoking
Current or former (n) 36 19 17 NS
Nonsmoker (n) 11 6 5
Body surface area (kg/m2), mean (SD) 1.75 (0, 22) 1.71 (0.21) 1.79 (0.23) NS
Performance status (n)
0–1 40 23 17 NS
2 7 2 5 NS
Carcinoma type
NSCLC 41 23 18 NS
Adenocarcinoma (n) 26 15 11
BAC (n) 5 5 0
Other (n) 10 3 7
Mesothelioma 4 1 4 NS
Thymus carcinoma stage IIIb 1 1 0 NS
Pemetrexed: line of treatment (n)
First line 23 10 13 NS
Second line or more 24 15 9 NS
Cycles of pemetrexed (n), median (IQR) 6 (4.5–11) 7 (6–13) 5.5 (3–6) 0.028/NS
Response to pemetrexed (n)
Disease control (CR  PR  SD) 38 20 18 NS
Progressive disease 2 0 2
Nonestablished 7 5 2
UV, univariate; MV, multivariate; IQR, interquartile range; NS, nonsignificant; SD, standard deviation; CR, complete
response; PR, partial response; SD, stable disease; BAC, bronchioalveolar carcinoma; NSCLC, non-small cell lung cancer.
TABLE 2. Incidence of Cutaneous Adverse Events (CAEs)
Related to Pemetrexed
CAEs among the Total
Population (n  107)
CAEs among the Alive
Population (n  47)
Conjunctivitis 27/107 (25%) 21/47 (44%)
Grade 0 10 4
Grade 1 20 14
Grade 2 7 7
Grade 3 0 0
Periorbital edema 16/107 (15%) 14/47 (30%)
Grade 0 21 11
Grade 1 12 11
Grade 2 4 3
Grade 3 0 0
Edema of the limbs 14/107 (13%) 12/47 (25%)
Grade 0 23 13
Grade 1 10 8
Grade 2 3 3
Grade 3 1 1
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CAEs had a cumulative profile, i.e., toxicity increased as the
number of cycles increased.
DISCUSSION
Pemetrexed is a novel chemotherapy that is widely used
in NSCLC and MPM. Because of its favorable toxicity
profile, chemotherapy may be continued after four to six
cycles in patients presenting with tumor control: these pa-
tients may then suffer more frequent unexpected toxicities. In
October 2008, we observed a life-threatening pemetrexed-
induced CAE with fluid retention in one of our patients,
which occurred after 15 cycles of chemotherapy. The argu-
ments that support a link between pemetrexed and this CAE
include (1) a previous similar report11; (2) a relapse of the
CAE by 1 week after each cycle of pemetrexed, with total or
partial reversibility at the end of each cycle; (3) exclusion of
other diagnoses of fluid retention by the heart, or liver or
kidney failure, and inflammatory edema; and (4) a favorable
outcome after stopping pemetrexed.
The aim of this study was to evaluate the most relevant
skin manifestations associated with pemetrexed, i.e., conjunc-
tivitis, periorbital edema, and edema of the limbs, excluding
cases of erythema, pruritus, and eczema. This is, to our
knowledge, the first study to focus on the incidence and risk
factors associated with pemetrexed-induced CAE in a cohort
of 107 patients receiving at least four cycles of pemetrexed.
In this study, pemetrexed-induced CAEs were reported in 37
of 107 (35%) patients from the TP and in 25 of 47 (53%) of
AP patients. A quarter of the alive patients had a grade 2/3
CAE that had an impact on daily activities. The prospective
nature of the cohort minimized the selection bias. Among
alive patients, 19 of 47 (40%) continued treatment with
pemetrexed during monitoring, without risk of memory bias.
Nevertheless, data concerning 28 of 47 alive patients (60%)
were retrospectively collected, with a risk of bias on memory,
recall, and classification, particularly on the assessment of
dermatological signs and grades.
Conjunctivitis was the first diagnosed CAE and may be
considered as an early marker for inflammatory edemas.
Inflammatory edema of the extremities was less frequent.
Edema is not a specific adverse event of pemetrexed and may
be induced by gemcitabine (20% of patients)20 and docetaxel
(47% of patients).21,22 Nevertheless, few incidences of sclero-
derma-like edema that are secondary to fluid retention have
been reported to be induced by gemcitabine23,24 or do-
cetaxel.22,25 As in the index case, the clinical presentation of
acral inflammatory edema in the literature is stereotyped,
consisting of an initial inflammatory phase, associated with
an edema, and followed rarely by scleroderma-like changes
and pigmentation of the skin as a result of chronic inflam-
mation. In this case of pemetrexed-induced CAE, the inflam-
mation was not only local (eyes and skin) but was also
systemic with mild fever, myositis, and an increased level of
inflammatory biomarkers.
More interestingly, the severity of CAEs, but not the
incidence, increases with the number of cycles of pem-
etrexed. CAEs did not seem to be correlated with hemato-
logical toxicities associated with folate and vitamin B12
deficiency.6 In multivariate analysis, women had a signifi-
cantly higher risk of developing CAEs induced by pem-
etrexed. As women with lung cancer have a better prognosis
than men, regardless of treatment, a longer survival time
FIGURE 3. Periorbital and facial edema.
FIGURE 2. A and B, Inflammatory edema of the abdomen
and limbs. C, Improvement of the inflammatory edemas af-
ter the treatment. Persistence of brownish thickened skin of
the legs.
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leads to longer exposure to chemotherapy drugs and, there-
fore, to the higher risk rate of toxicity. Nevertheless, this
result could also reflect a gender-related difference in pem-
etrexed-induced adverse reactions, as has been shown for
other drugs (anesthetics, human immunodeficiency virus-1
therapies, and antiarrhythmics principally).26,27 The reasons
for these increased risks in women are not yet known but
could be linked to gender-related differences in pharmacoki-
netics or differences in the use of medications by women.
Finally, we also observed that, among 15 patients
previously treated by gemcitabine, seven developed pem-
etrexed-induced CAE, which included six cases of grade 2/3
CAE. As gemcitabine and pemetrexed can induce scleroderma-
like edemas, patients treated with both drugs may have a
cumulative risk of severe CAE. Because no patient received
gemcitabine and pemetrexed concomitantly, scleroderma-like
edemas cannot be explained by the increased cytotoxic effect
of gemcitabine when combined with pemetrexed.28 Sclero-
derma-like edemas may not be explained by pharmacologic
antifolate cytotoxicity, as it is not specific to the antifolate
therapeutic class. Rather, they may be explained by nonspe-
cific systemic inflammation with capillary leakage, which
leads to the complex mechanisms described in the pathogen-
esis of scleroderma, such as extracellular-matrix overproduc-
tion by activated fibroblasts of the skin.29
Pemetrexed-induced CAEs are frequent but usually do
not result in the need for discontinuation of pemetrexed.
Nevertheless, the CAE must be treated to avoid chronic
cutaneous and systemic inflammation and to improve quality
of life. In our experience, grade 1 and grade 2 CAEs can be
managed with symptomatic treatments. Sodium cromogly-
cate for conjunctivitis and topical corticosteroid for cutaneous
inflammation are well tolerated and can be used at the onset
of symptoms. Emollient cream and compression stockings
TABLE 3. Characteristics of Patients with Grade 2/3 CAEs Related to Pemetrexed
1 2 3 4 5 6 7 8 9 10 11
Clinical characteristics
Age 68 69 58 70 52 61 56 66 69 69 64
Gender M F F M M F F M M F M
Body surface area (kg/m2) 1.9 1.4 1.6 1.8 1.6 1.4 1.4 2.2 1.8 1.7 1.9
NSCLC typea 2 1 1 1 3 1 3 1 2 2 1
Weight change (kg) 1 0 1 10 8 3 6 11 17 2 6
Hemoglobin change (g/dl) 0.7 11 1.3 0.8 1.4 1.4 1.1 0.3 2.8 0.2 0.4
eGFR before pemetrexed (ml/min) 46 68 38 66 61 52 63 76 74 63 88
eGFR change (ml/min) 6 4 3 11 18 7 2 12 2 2 5
Treatment
Line of treatment with pemetrexed 3 1 2 3 2 2 2 2 3 2 1
Cycles of pemetrexed (n) 13 16 6 11 9 7 28 28 17 6 6
Response to pemetrexedb PR PR PR PR SD PR PR SD SD SD PR
Other chemotherapies received
Cisplatin or carboplatin 1 1 1 1 1 1 1 1 1 1 1
Paclitaxel 1 1
Erlotinib 1 1 1 1
Gemcitabine 1 1 1 1 1 1
Vinorelbine 1
Cutaneous adverse events
Grade of conjunctivitis (0–3) 1 2 2 2 2 2 2 1 1 2 0
Grade of periorbital edema (0–3) 2 0 2 1 1 0 0 1 1 2 0
Grade of edema of the limbs (0 to 3) 2 0 1 0 0 0 1 2 3 1 2
Time of onset of first adverse event (months) 4 2 1 3 1 0.5 12 5 1 2 1.5
a 1, adenocarcinoma; 2, bronchioalveolar carcinoma; 3, large cell carcinoma.
b Best response; PR, partial response; SD, stable disease.
NSCLC, non-small cell lung cancer; CAE, cutaneous adverse event.
TABLE 4. Proposal of Treatment for Grade 1 and
Grade 2 CAEsa
Conjunctivitis
First-line treatment: sodium cromoglycate 2% eye drops (four times daily)
Second-line treatment: corticosteroid eye drops prescribed by an
ophthalmologist
Cutaneous inflammation of the limbs and/or pruritus
First-line treatment: emollient cream
Second-line treatment: topical corticosteroid (group III, e.g.,
betamethasone dipropionate 0.05%) once daily
Edema of the lower limbs
First-line treatment: emollient cream and grade II compression stockings
Second-line treatment: lymphatic drainage
Periorbital and facial edema: topical corticosteroid (group V, e.g.,
desonide 0.05%) once daily
a This treatment should be used until symptoms resolve. It may also be given as a
preventive therapy after each course of pemetrexed.
CAE, cutaneous adverse event.
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are indicated in cases of edema of the extremities (Table 4).
Optimal management of CAEs may help to continue pem-
etrexed treatment if indicated.
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